Agency Forms Undergoing Paperwork Reduction Act Review, 80900-80903 [2024-22958]
Download as PDF
<![CDATA[
80900
Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices
Shoemaker, Chief, Banking and
Regulatory Policy, 202–898–6962,
kashoemaker@fdic.gov; Legal Division:
Sheikha Kapoor, Assistant General
Counsel, 202–898–3960, skapoor@
fdic.gov; Vivek Khare, Senior Counsel,
202–898–6847; or Ryan McCarthy,
Counsel, 202–898–7301, rymccarthy@
fdic.gov.
On August
6, 2024, the FDIC published in the
Federal Register an RFI and comment
soliciting comments on deposit data that
is not currently reported in the FFIEC
Call Report or other regulatory reports,
including for uninsured deposits. The
FDIC issued the RFI to seek information
on the characteristics that affect the
stability and franchise value of different
types of deposits and whether more
detailed or more frequent reporting on
these characteristics or types of deposits
SUPPLEMENTARY INFORMATION:
could enhance offsite risk and liquidity
monitoring, inform analysis of the
benefits and costs associated with
additional deposit insurance coverage
for certain types of deposits, improve
risk sensitivity in deposit insurance
pricing, and provide analysts and the
general public with accurate and
transparent data. The RFI stated that the
comment period would close on
October 7, 2024. The FDIC has received
requests to extend the comment period.
An extension of the comment period
will allow interested parties additional
time to prepare information and
comments. Therefore, the FDIC is
extending the end of the comment
period for the RFI from October 7, 2024,
to December 6, 2024.
Federal Deposit Insurance Corporation.
Dated at Washington, DC, on October 1,
2024.
James P. Sheesley,
Assistant Executive Secretary.
[FR Doc. 2024–23010 Filed 10–3–24; 8:45 am]
BILLING CODE 6714–01–P
FEDERAL DEPOSIT INSURANCE
CORPORATION
Notice of Termination of Receiverships
The Federal Deposit Insurance
Corporation (FDIC or Receiver), as
Receiver for each of the following
insured depository institutions, was
charged with the duty of winding up the
affairs of the former institutions and
liquidating all related assets. The
Receiver has fulfilled its obligations and
made all dividend distributions
required by law.
NOTICE OF TERMINATION OF RECEIVERSHIPS
Fund
Receivership name
City
10221 ...................................................................
10486 ...................................................................
10524 ...................................................................
Lincoln Park Savings Bank ....................
Community South Bank .........................
Seaway Bank and Trust Company ........
Chicago ..................
Parsons ..................
Chicago ..................
The Receiver has further irrevocably
authorized and appointed FDICCorporate as its attorney-in-fact to
execute and file any and all documents
that may be required to be executed by
the Receiver which FDIC-Corporate, in
its sole discretion, deems necessary,
including but not limited to releases,
discharges, satisfactions, endorsements,
assignments, and deeds. Effective on the
termination dates listed above, the
Receiverships have been terminated, the
Receiver has been discharged, and the
Receiverships have ceased to exist as
legal entities.
(Authority: 12 U.S.C. 1819)
Federal Deposit Insurance Corporation.
Dated at Washington, DC, on October 1,
2024.
James P. Sheesley,
Assistant Executive Secretary.
[FR Doc. 2024–22964 Filed 10–3–24; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
BILLING CODE 6714–01–P
VerDate Sep<11>2014
17:26 Oct 03, 2024
Jkt 265001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–1310]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Public Health
Laboratory Testing for Emerging
Antibiotic Resistance and Fungal
Threats’’ to the Office of Management
and Budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on June 17,
2024 to obtain comments from the
public and affected agencies. CDC did
not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
State
IL
TN
IL
Termination date
10/01/2024
10/01/2024
10/01/2024
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
E:\FR\FM\04OCN1.SGM
04OCN1
80901
Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Public Health Laboratory Testing for
Emerging Antibiotic Resistance and
Fungal Threats (0920–1310, Exp. 5/31/
2026)—Revision—National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Antimicrobial resistance has the
potential to impact all Americans at
every stage of life and the Centers for
Disease Control and Prevention (CDC) is
working to drive aggressive action and
empower the nation to comprehensively
respond to these threats. The National
Action Plan Sub-Objective 2.1.1
describes creation of ‘‘a regional public
health laboratory network that uses
standardized testing platforms to
expand the availability of reference
testing services’’, and facilitation of
‘‘rapid data analysis and dissemination
of information.’’ The CDC has created
this public health laboratory network
and named it the Antimicrobial
Resistance Laboratory Network (AR Lab
Network). The mission of the AR Lab
Network is to offer validated highquality laboratory testing through
funding support of state and regional
labs so these labs can build the capacity
and the capability to locally improve
detection and laboratory diagnostics.
Building strength nationally through
public health laboratories thereby
increases the capacity of state and local
health departments for rapid detection
and faster response to outbreaks and
Laboratories are financially supported
through the Epidemiology and
Laboratory Capacity for Prevention and
Control of Emerging Infectious Diseases
(ELC) Cooperative agreement (CDC–
RFA–CK–24–0002) to perform testing,
support workforce, and laboratory
infrastructure. Laboratory capacity
supported through the AR Lab Network
fall into the following categories: (1)
core testing, support for important
antimicrobial resistant pathogens that
are traditionally healthcare-associated,
including carbapenem-resistant
Enterobacteriaceae (CRE), carbapenemresistant Pseudomonas aeruginosa
(CRPA), carbapenem-resistant
Acinetobacter baumannii (CRAB), and
Candida species, including C. auris; (2)
jurisdictional testing capacity that
supports Neisseria gonorrhoeae
surveillance; (3) testing of colonization
screening samples to support local
public health response; and (4)
enhanced testing capacity at the
regional laboratories (currently seven).
CDC is requesting a three-year
approval for revisions made to OMB
Control No. 0920–1310 for the Public
Health Laboratory Testing for Emerging
Antibiotic Resistance and Fungal
Threats which supports the data
collected through the Antimicrobial
Resistance Laboratory Network (AR Lab
Network). A Revision is being submitted
to: (1) add new data elements to the data
collection forms: (2) ensure that the
burden of generating electronic
messages for data transmission are
accounted for; and (3) accommodate
changes to the Performance Measures
(PMs) used to monitor the performance
of the AR Lab Network. For this
Revision, the total estimated annual
burden is 57,872 hours. There are no
costs to respondents other than their
time.
emerging antimicrobial resistance
among bacterial and fungal pathogens
(https://www.cdc.gov/antimicrobialresistance/media/pdfs/2019-ar-threatsreport-508.pdf). This state and local
public health laboratory testing capacity
is being implemented by the
Department of Health and Human
Services (HHS), Centers for Disease
Control and Prevention (CDC) in
response to the Executive Order 13676
of September 18, 2014, the National
Strategy of September 2014 and to
implement the National Action Plan of
October 2020 for Combating AntibioticResistant Bacteria. Data collected
throughout this network is also
authorized by Section 301 of the Public
Health Service Act (42 U.S.C. 241).
The CDC’s AR Lab Network supports
nationwide lab capacity to rapidly
detect antimicrobial resistance and
inform local public health responses to
prevent spread and protect people. It
closes the gap between local laboratory
capabilities and the data needed to
combat antimicrobial resistance by
providing comprehensive lab capacity
and infrastructure for detecting
antimicrobial-resistant pathogens
(germs), advanced technology, like DNA
sequencing, and rapid sharing of
actionable data to drive infection
control responses and help treat
infections. This infrastructure allows
the public health community to rapidly
detect emerging antimicrobial-resistant
threats in healthcare, food, and the
community, mount a comprehensive
local response, and better understand
these deadly threats to quickly contain
them.
The AR Lab Network is a network of
jurisdictional public health laboratories
currently including those of all 50
states, District of Columbia, Los Angeles
County, Houston, New York City,
Philadelphia, Guam, and Puerto Rico.
khammond on DSKJM1Z7X2PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondents
Form name
Public Health Laboratories ..............
I.1—ROUTINE TESTING BY GENERAL IN JURISDICTION—Annual Evaluation and Performance
Measurement Report.
1.2—EXPANDED DRUG SUSCEPTIBILITY TESTING (ExAST) IN JURISDICTION—Annual Evaluation and Performance Measurement Report.
1.3—CANDIDA SPECIES IDENTIFICATION IN JURISDICTION—Annual Evaluation and Performance
Measurement Report.
1.4—HAIAR WHOLE GENOME SEQUENCING
(WGS) OF GRAM–NEGATIVE AR THREATS IN
JURISDICTION—Annual Evaluation and Performance Measurement Report.
VerDate Sep<11>2014
17:26 Oct 03, 2024
Jkt 265001
PO 00000
Frm 00047
Fmt 4703
Average
number of
responses per
respondent
Number of
respondents
Sfmt 4703
Average
burden per
response
(in hours)
57
1
10/60
7
1
10/60
57
1
10/60
Up to 57
1
10/60
E:\FR\FM\04OCN1.SGM
04OCN1
80902
Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
khammond on DSKJM1Z7X2PROD with NOTICES
Type of
respondents
1.5—C. AURIS COLONIZATION SCREENING IN
JURISDICTION—Annual Evaluation and Performance Measurement Report.
1.6—CARBAPENEMASE–PRODUCING ORGANISM
(CPO) SCREENING IN JURISDICTION—Annual
Evaluation and Performance Measurement Report.
1.7—AZOLE RESISTANCE IN CLINICAL ASPERGILLUS FUMIGATUS ISOLATES—Annual Evaluation and Performance Measurement Report.
1.8—N. GONORRHOEAE WHOLE GENOME SEQUENCING (WGS)—Annual Evaluation and Performance Measurement Report.
1.9—GONOCOCCAL (GC) ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) IN JURISDICTION—Annual Evaluation and Performance Measurement Report.
1.10—WHOLE GENOME SEQUENCING (WGS) OF
S. PNEUMONAIE—Annual Evaluation and Performance Measurement Report.
1.11—CLOSTRIDIOIDES DIFFICILE (C. DIFFICLE)
TESTING IN JURISDICTION—Annual Evaluation
and Performance Measurement Report.
1.12—ANTIFUNGAL RESISTANT TINEA
DERMATOPHYTES—Annual Evaluation and Performance Measurement Report.
1.13—ANTIMICROBIAL SUSCEPTIBILITY TESTING
(AST) OF INVASIVE HAEMOPHILUS
INFLUENZAE (H. INFLUENZAE) IN JURISDICTION—Annual Evaluation and Performance Measurement Report.
1.14—MYCOPLASMA GENTALIUM (MG)—Annual
Evaluation and Performance Measurement Report.
1.15—MOLECULAR Mtb TESTING—Annual Evaluation and Performance Measurement Report.
1.16—C. AURIS WHOLE GENOME SEQUENCING
(WGS) IN JURISDICTION—Annual Evaluation and
Performance Measurement Report.
1.17—MONITORING CRE CRPA IN COMPANION
ANIMALS TO FROM HUMANS—Annual Evaluation and Performance Measurement Report.
1.18—HEALTHCARE WASTEWATER–BASED SURVEILLANCE—Annual Evaluation and Performance
Measurement Report.
1.19—COMMUNICATION AND COORDINATION OF
ACTIONABLE EPI LAB DATA IN JURISDICTION—Annual Evaluation and Performance Measurement Report.
1.20—CHARACTERIZATION OF THE CLINICAL
LABORATORY NETWORK IN JURISDICTION—
Annual Evaluation and Performance Measurement
Report.
1.21 NEISSERIA GONORRHOEAE ETEST FOR
SHARP.
AR Lab Network Annual Report of Testing Methods
for Carbapenemase-producing Organisms.
AR Lab Network Monthly Data Report Form for
Carbapenemase-producing Organisms.
AR Lab Network Alert Report Form for
Carbapenemase-producing Organisms.
AR Lab Network Alert and Monthly Data Report Form
for Candida.
AR Lab Network Form for Phylogenetic Tree-level
Mycotics Reporting.
AR Lab Network Alert and Monthly Data Report Form
for Neisseria gonorrhoeae.
AR Lab Network DAART data elements for Neisseria
gonorrhoeae.
HL7 Messages updates—IT Maintenance ..................
VerDate Sep<11>2014
17:26 Oct 03, 2024
Jkt 265001
PO 00000
Frm 00048
Fmt 4703
Average
number of
responses per
respondent
Number of
respondents
Form name
Sfmt 4703
Average
burden per
response
(in hours)
Up to 57
1
10/60
Up to 57
1
10/60
2
1
20/60
4
1
10/60
4
1
20/60
2
1
20/60
2
1
20/60
3
1
20/60
2
1
20/60
4
1
20/60
Up to 20
1
10/60
Up to 57
1
10/60
Up to 2
1
20/60
Up to 2
1
20/60
57
1
10/60
57
1
10/60
17
1
20/60
57
1
2
57
1302
20/60
57
214
3/60
Up to 57
1671
20/60
Up to 57
30
6/60
17
93
6/60
4
50
10/60
32
4
20/60
E:\FR\FM\04OCN1.SGM
04OCN1
80903
Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Type of
respondents
Number of
respondents
Form name
Implementation of new HL7 messages—IT Initial Set
up.
CSV files updates for Carbapenemase-producing organisms—IT Maintenance.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–22958 Filed 10–3–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–R–65]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
December 3, 2024.
ADDRESSES: When commenting, please
reference the document identifier or
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:26 Oct 03, 2024
Jkt 265001
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address:
CMS, Office of Strategic Operations and
Regulatory Affairs, Division of
Regulations Development, Attention:
Document Identifier/OMB Control
Number: Room C4–26–05, 7500
Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–R–65 Final Peer Review
Organizations Sanction and Supporting
Regulations
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Average
number of
responses per
respondent
Average
burden per
response
(in hours)
11
4
3
24
1
1
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collections
1. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Final Peer
Review Organizations Sanction and
Supporting Regulations; Use: The Peer
Review Improvement Act of 1982
amended Title XI of the Social Security
Act (the Act), creating the Utilization
and Quality Control Peer Review
Organization Program. Section 1156 of
the Act imposes obligations on health
care practitioners and others who
furnish or order services or items under
Medicare. This section also provides for
sanction actions, if the Secretary
determines that the obligations as stated
by this section are not met. Quality
Improvement Organizations (QIOs) are
responsible for identifying violations.
The QIOs may allow practitioners or
other entities, opportunities to submit
relevant information before determining
that a violation has occurred. The
information collection requirements
contained in this information collection
request are used by the QIOs to collect
the information necessary to make their
decision. Form Number: CMS–R–65
(OMB control number: 0938–0444);
Frequency: Occasionally; Affected
Public: Private sector—Business or other
for-profit and Not-for-profit institutions;
Number of Respondents: 34; Total
Annual Responses: 34; Total Annual
Hours: 8,144. (For policy questions
E:\FR\FM\04OCN1.SGM
04OCN1
]]>Agencies
[Federal Register Volume 89, Number 193 (Friday, October 4, 2024)]
[Notices]
[Pages 80900-80903]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22958]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-24-1310]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Public Health Laboratory Testing for
Emerging Antibiotic Resistance and Fungal Threats'' to the Office of
Management and Budget (OMB) for review and approval. CDC previously
published a ``Proposed Data Collection Submitted for Public Comment and
Recommendations'' notice on June 17, 2024 to obtain comments from the
public and affected agencies. CDC did not receive comments related to
the previous notice. This notice serves to allow an additional 30 days
for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding
[[Page 80901]]
the items contained in this notice to the Attention: CDC Desk Officer,
Office of Management and Budget, 725 17th Street NW, Washington, DC
20503 or by fax to (202) 395-5806. Provide written comments within 30
days of notice publication.
Proposed Project
Public Health Laboratory Testing for Emerging Antibiotic Resistance
and Fungal Threats (0920-1310, Exp. 5/31/2026)--Revision--National
Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers
for Disease Control and Prevention (CDC).
Background and Brief Description
Antimicrobial resistance has the potential to impact all Americans
at every stage of life and the Centers for Disease Control and
Prevention (CDC) is working to drive aggressive action and empower the
nation to comprehensively respond to these threats. The National Action
Plan Sub-Objective 2.1.1 describes creation of ``a regional public
health laboratory network that uses standardized testing platforms to
expand the availability of reference testing services'', and
facilitation of ``rapid data analysis and dissemination of
information.'' The CDC has created this public health laboratory
network and named it the Antimicrobial Resistance Laboratory Network
(AR Lab Network). The mission of the AR Lab Network is to offer
validated high-quality laboratory testing through funding support of
state and regional labs so these labs can build the capacity and the
capability to locally improve detection and laboratory diagnostics.
Building strength nationally through public health laboratories thereby
increases the capacity of state and local health departments for rapid
detection and faster response to outbreaks and emerging antimicrobial
resistance among bacterial and fungal pathogens (https://www.cdc.gov/antimicrobial-resistance/media/pdfs/2019-ar-threats-report-508.pdf).
This state and local public health laboratory testing capacity is being
implemented by the Department of Health and Human Services (HHS),
Centers for Disease Control and Prevention (CDC) in response to the
Executive Order 13676 of September 18, 2014, the National Strategy of
September 2014 and to implement the National Action Plan of October
2020 for Combating Antibiotic-Resistant Bacteria. Data collected
throughout this network is also authorized by Section 301 of the Public
Health Service Act (42 U.S.C. 241).
The CDC's AR Lab Network supports nationwide lab capacity to
rapidly detect antimicrobial resistance and inform local public health
responses to prevent spread and protect people. It closes the gap
between local laboratory capabilities and the data needed to combat
antimicrobial resistance by providing comprehensive lab capacity and
infrastructure for detecting antimicrobial-resistant pathogens (germs),
advanced technology, like DNA sequencing, and rapid sharing of
actionable data to drive infection control responses and help treat
infections. This infrastructure allows the public health community to
rapidly detect emerging antimicrobial-resistant threats in healthcare,
food, and the community, mount a comprehensive local response, and
better understand these deadly threats to quickly contain them.
The AR Lab Network is a network of jurisdictional public health
laboratories currently including those of all 50 states, District of
Columbia, Los Angeles County, Houston, New York City, Philadelphia,
Guam, and Puerto Rico. Laboratories are financially supported through
the Epidemiology and Laboratory Capacity for Prevention and Control of
Emerging Infectious Diseases (ELC) Cooperative agreement (CDC-RFA-CK-
24-0002) to perform testing, support workforce, and laboratory
infrastructure. Laboratory capacity supported through the AR Lab
Network fall into the following categories: (1) core testing, support
for important antimicrobial resistant pathogens that are traditionally
healthcare-associated, including carbapenem-resistant
Enterobacteriaceae (CRE), carbapenem-resistant Pseudomonas aeruginosa
(CRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), and
Candida species, including C. auris; (2) jurisdictional testing
capacity that supports Neisseria gonorrhoeae surveillance; (3) testing
of colonization screening samples to support local public health
response; and (4) enhanced testing capacity at the regional
laboratories (currently seven).
CDC is requesting a three-year approval for revisions made to OMB
Control No. 0920-1310 for the Public Health Laboratory Testing for
Emerging Antibiotic Resistance and Fungal Threats which supports the
data collected through the Antimicrobial Resistance Laboratory Network
(AR Lab Network). A Revision is being submitted to: (1) add new data
elements to the data collection forms: (2) ensure that the burden of
generating electronic messages for data transmission are accounted for;
and (3) accommodate changes to the Performance Measures (PMs) used to
monitor the performance of the AR Lab Network. For this Revision, the
total estimated annual burden is 57,872 hours. There are no costs to
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average number Average burden
Type of respondents Form name Number of of responses per response
respondents per respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Public Health Laboratories........... I.1--ROUTINE TESTING BY 57 1 10/60
GENERAL IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.2--EXPANDED DRUG 7 1 10/60
SUSCEPTIBILITY TESTING
(ExAST) IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.3--CANDIDA SPECIES 57 1 10/60
IDENTIFICATION IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.4--HAIAR WHOLE GENOME Up to 57 1 10/60
SEQUENCING (WGS) OF
GRAM-NEGATIVE AR
THREATS IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
[[Page 80902]]
1.5--C. AURIS Up to 57 1 10/60
COLONIZATION SCREENING
IN JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.6--CARBAPENEMASE-PRODU Up to 57 1 10/60
CING ORGANISM (CPO)
SCREENING IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.7--AZOLE RESISTANCE IN 2 1 20/60
CLINICAL ASPERGILLUS
FUMIGATUS ISOLATES--
Annual Evaluation and
Performance Measurement
Report.
1.8--N. GONORRHOEAE 4 1 10/60
WHOLE GENOME SEQUENCING
(WGS)--Annual
Evaluation and
Performance Measurement
Report.
1.9--GONOCOCCAL (GC) 4 1 20/60
ANTIMICROBIAL
SUSCEPTIBILITY TESTING
(AST) IN JURISDICTION--
Annual Evaluation and
Performance Measurement
Report.
1.10--WHOLE GENOME 2 1 20/60
SEQUENCING (WGS) OF S.
PNEUMONAIE--Annual
Evaluation and
Performance Measurement
Report.
1.11--CLOSTRIDIOIDES 2 1 20/60
DIFFICILE (C. DIFFICLE)
TESTING IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.12--ANTIFUNGAL 3 1 20/60
RESISTANT TINEA
DERMATOPHYTES--Annual
Evaluation and
Performance Measurement
Report.
1.13--ANTIMICROBIAL 2 1 20/60
SUSCEPTIBILITY TESTING
(AST) OF INVASIVE
HAEMOPHILUS INFLUENZAE
(H. INFLUENZAE) IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.14--MYCOPLASMA 4 1 20/60
GENTALIUM (MG)--Annual
Evaluation and
Performance Measurement
Report.
1.15--MOLECULAR Mtb Up to 20 1 10/60
TESTING--Annual
Evaluation and
Performance Measurement
Report.
1.16--C. AURIS WHOLE Up to 57 1 10/60
GENOME SEQUENCING (WGS)
IN JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.17--MONITORING CRE Up to 2 1 20/60
CRPA IN COMPANION
ANIMALS TO FROM HUMANS--
Annual Evaluation and
Performance Measurement
Report.
1.18--HEALTHCARE Up to 2 1 20/60
WASTEWATER-BASED
SURVEILLANCE--Annual
Evaluation and
Performance Measurement
Report.
1.19--COMMUNICATION AND 57 1 10/60
COORDINATION OF
ACTIONABLE EPI LAB DATA
IN JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.20--CHARACTERIZATION 57 1 10/60
OF THE CLINICAL
LABORATORY NETWORK IN
JURISDICTION--Annual
Evaluation and
Performance Measurement
Report.
1.21 NEISSERIA 17 1 20/60
GONORRHOEAE ETEST FOR
SHARP.
AR Lab Network Annual 57 1 2
Report of Testing
Methods for
Carbapenemase-producing
Organisms.
AR Lab Network Monthly 57 1302 20/60
Data Report Form for
Carbapenemase-producing
Organisms.
AR Lab Network Alert 57 214 3/60
Report Form for
Carbapenemase-producing
Organisms.
AR Lab Network Alert and Up to 57 1671 20/60
Monthly Data Report
Form for Candida.
AR Lab Network Form for Up to 57 30 6/60
Phylogenetic Tree-level
Mycotics Reporting.
AR Lab Network Alert and 17 93 6/60
Monthly Data Report
Form for Neisseria
gonorrhoeae.
AR Lab Network DAART 4 50 10/60
data elements for
Neisseria gonorrhoeae.
HL7 Messages updates--IT 32 4 20/60
Maintenance.
[[Page 80903]]
Implementation of new 11 4 3
HL7 messages--IT
Initial Set up.
CSV files updates for 24 1 1
Carbapenemase-producing
organisms--IT
Maintenance.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-22958 Filed 10-3-24; 8:45 am]
BILLING CODE 4163-18-P
